"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." December 11, 2025
The Wegovy patient leaflet says it acts on receptors in the brain that control appetite, causing people to feel fuller, less hungry and experience less craving for food [3]
The glucagon receptor agonism in retatrutide introduces additional considerations not seen with GLP-1-only agents
Retatrutide is an advanced investigational peptide known for its triple hormone receptor activity, targeting
Not every patient who used a GLP-1 drug will qualify for legal action
Cant wait to See my results Im taking GHK-Cu for my skin, hair and nails